Radiks

Radiks Therapeutics is a biotechnology company focused on the discovery and development of next-generation targeted protein degraders to treat cancer and other life-threatening diseases. The company utilizes a proprietary platform to design small molecule degraders, including PROTACs and molecular glues, that can eliminate disease-causing proteins previously considered undruggable. Founded by Dr. Shaomeng Wang, a renowned expert in medicinal chemistry and protein degradation, Radiks aims to advance a pipeline of innovative therapies from discovery into clinical development. The company is headquartered in Ann Arbor, Michigan, and leverages deep expertise in structure-based drug design to optimize its therapeutic candidates.